Propel Bio Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q3 2024
A detailed history of Propel Bio Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 869,927 shares of PHAT stock, worth $6.48 Million. This represents 9.12% of its overall portfolio holdings.
Number of Shares
869,927
Previous 869,927
-0.0%
Holding current value
$6.48 Million
Previous $8.96 Billion
75.53%
% of portfolio
9.12%
Previous 5.81%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$75.3 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$55.6 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$43.7 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$30.5 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$26.1 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $292M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...